Serina Therapeutics (NYSEAMERICAN:SER) Releases Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) posted its quarterly earnings results on Thursday. The company reported ($0.58) EPS for the quarter, FiscalAI reports.

Serina Therapeutics Stock Up 10.3%

Shares of NYSEAMERICAN:SER traded up $0.16 during midday trading on Thursday, hitting $1.72. 170,868 shares of the stock were exchanged, compared to its average volume of 66,928. The company has a market cap of $25.63 million, a P/E ratio of -0.90 and a beta of 1.15. Serina Therapeutics has a 52-week low of $1.22 and a 52-week high of $7.92. The stock’s fifty day moving average is $1.93.

Insider Buying and Selling

In other Serina Therapeutics news, insider Randall Moreadith sold 39,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $2.50, for a total value of $97,500.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 17.00% of the stock is owned by company insiders.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.